Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label Pharmaceuticals. Show all posts
Showing posts with label Pharmaceuticals. Show all posts
Tuesday, December 31, 2013

Grading Pharma In 2013: Gilead's hepatitis C collaboration with Bristol had ethical issues

›
Grading Pharma In 2013: 16 Drug Companies Ranked Matthew Herper     I gave one A+, to Bristol-Myers Squibb, based on its overall perf...
Tuesday, December 17, 2013

Investment Commentary - Can Abbvie Trump Gilead's HCV Lead?

›
Investment Commentary Related; Analysis: Fight for cheap drugs shifts from AIDS to new hepatitis pills LONDON (Reuters) - A new battle...
Wednesday, December 11, 2013

Transcript HCV Drugs - Achillion and Idenix presents at Oppenheimer 24th Annual Healthcare Conference

›
Hello folks, Both, Achillion  and Idenix   presented at Oppenheimer 24th Annual Healthcare Conference, transcripts  are  available over at ...
Friday, December 6, 2013

What Everybody Ought to Know About Gilead and Johnson's New Hepatitis C Drugs

›
 Investment Commentary What Everybody Ought to Know About Gilead and Johnson's New Hepatitis C Drugs By Todd Campbell December 6, 201...
Friday, November 8, 2013

Bristol-Myers Squibb will stop research to discover new drugs for hepatitis C

›
Bristol to stop early research in three disease areas Thu Nov 7, 2013 6:47pm EST Nov 7 ( Reuters ) - Bristol-Myers Squibb Co said on Thu...
Wednesday, September 11, 2013

Investment Commentary; Sofosbuvir- Gilead's Lurking Hepatitis C Megablockbuster Drug

›
Investment Commentary In this video, health care analysts David Williamson and Max Macaluso drill down on Gilead's strong drug develo...
Tuesday, September 10, 2013

Boehringer Ingelheim broadens efforts for interferon-free hepatitis C treatments through clinical collaboration with Presidio Pharmaceuticals

›
Related: Boehringer Ingelheim HCV Drug Development Program 10 September 2013 Boehringer Ingelheim broadens efforts for interferon-free ...
Friday, September 6, 2013

Sofosbuvir: Firms Spar Over Hepatitis Drug

›
  Volume 91 Issue 36 | p. 16 | News of The Week Issue Date: September 9, 2013 | Web Date: September 5, 2013 Source - Chemical and Engin...
1 comment:
Saturday, August 31, 2013

Merck demand triggers expanding patent war with Gilead over sofosbuvir

›
UPDATED: Merck demand triggers expanding patent war with Gilead over sofosbuvir August 31, 2013 | By John Carroll Gilead is rolling out...
Thursday, August 8, 2013

Gilead Sciences Carving Out a Wider Moat

›
Investment Commentary Gilead Sciences Carving Out a Wider Moat Stock Investor editor Matt Coffina and senior biotech analyst Karen Ander...
Tuesday, July 23, 2013

Plenty Of Room For Everyone In The Race To FDA Approval For New Hepatitis C Therapies

›
Investment Commentary Plenty Of Room For Everyone In The Race To FDA Approval For New Hepatitis C Therapies   Jul 23 2013, 12:32 Seeking Al...
Tuesday, June 25, 2013

Top Medicare Prescribers Rake In Speaking Fees From Drugmakers

›
Top Medicare Prescribers Rake In Speaking Fees From Drugmakers by Charles Ornstein , Tracy Weber and Jennifer LaFleur ProPublica, June ...
Wednesday, June 12, 2013

Inside HCV: An Interview with Janssen

›
Investment Commentary  @ Motley Fool   By Brandy Betz - June 12, 2013 | Tickers: GILD , JNJ , VRTX | 0 Comments Brandy is a...
Friday, May 31, 2013

Commentary: Gilead's agent is the holy grail of HCV treatment

›
Source - About Medical Marketing & Media Therapetic Focus: Infectious Diseases   Noah Pines May 31, 2013   Therapeuti...
Tuesday, April 16, 2013

Achillion -1 Biotech Challenging the Hep-C Goliath

›
Related Press Release - Achillion Initiates Phase 2 Interferon-Free Trial of Sovaprevir and ACH-3102 for Genotype 1 HCV Investment Commen...
Wednesday, March 27, 2013

Gilead-Medivir Hepatitis C Drug Clears Virus in Patients

›
Gilead-Medivir Hepatitis C Drug Clears Virus in Patients By Ryan Flinn & Shannon Pettypiece An automated machine works on purification o...